#67
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to assess cannabis use frequency in patients taking biologic therapies, as emerging evidence suggests cannabis may interact with inflammatory pathways that these medications target. Understanding these potential interactions is critical for optimizing treatment outcomes in patients with inflammatory conditions who use cannabis. Routine screening for cannabis use patterns should become standard practice when prescribing immunomodulatory medications.
# Summary
This article examines emerging health risks associated with contemporary cannabis use, highlighting the importance of clinicians understanding evolving safety profiles beyond traditional concerns. Modern cannabis products, particularly high-potency formulations, have been linked to increased inflammatory markers and may interact with biologic therapies commonly used in rheumatologic and immunologic conditions. The structured assessment approach described in the article—capturing frequency and patterns of cannabis use—provides a practical framework for clinical intake that can inform risk stratification and treatment planning. Given the growing prevalence of cannabis use among patients with chronic inflammatory conditions, clinicians should routinely inquire about cannabis consumption and remain alert to potential adverse interactions with immunosuppressive or biologic medications. Clinicians should integrate cannabis use assessment into standard history-taking and consider counseling patients about inflammation risks, particularly those on anti-inflammatory therapies where cannabis-induced inflammation could undermine treatment efficacy.
💊 The shifting potency and composition of modern cannabis products—particularly high-THC concentrates and novel cannabinoids—present evolving clinical considerations that differ meaningfully from historical cannabis use patterns. Healthcare providers should recognize that patient self-reported cannabis use may not capture the actual dose, formulation, or frequency of exposure, making it challenging to establish clear causal relationships between cannabis and specific adverse outcomes. The intersection of cannabis use with chronic inflammatory conditions and biologic therapies warrants careful attention, as emerging evidence suggests potential interactions with immune-modulating treatments, though mechanistic understanding remains incomplete. When taking cannabis use histories, clinicians should inquire specifically about product type, concentration, and consumption method rather than relying solely on frequency data, and should counsel patients on potential risks particularly if they are using immunosuppressive therapies. Integrating structured cannabis use assessment into standard clinical workflows—with attention to modern product characteristics—may help clinicians better identify patients at
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
